CPT® Code 86596

Voltage-gated calcium channel (VGCC) antibodies are a specific type of antibody that target the voltage-gated calcium channels in the body. These antibodies are primarily associated with Lambert-Eaton syndrome, a rare autoimmune disorder that affects the presynaptic nerve terminals, leading to significant muscle weakness, particularly in the extremities, as well as reduced tendon reflexes and various autonomic dysfunctions. In addition to Lambert-Eaton syndrome, VGCC antibodies are also linked to cerebellar degeneration, which can result in coordination and balance issues due to the impairment of the cerebellum's function. Notably, more than half of the patients who test positive for VGCC antibodies may also have an underlying neoplastic tumor, most commonly small cell lung cancer. VGCCs play a crucial role in the physiological process of depolarizing the cell membrane, which allows calcium ions to enter the cell in response to an action potential, thereby facilitating electrical signaling and initiating various cellular mechanisms. These calcium channels are present in various tissues, including smooth and skeletal muscle fibers, endocrine cells, and nerve cells. The detection of VGCC antibodies is typically performed using a radioimmunoassay, which can identify these antibodies in up to 90% of patients with Eaton-Lambert syndrome, as well as in all patients who have both Eaton-Lambert syndrome and small cell lung cancer. In this assay, radiolabeled antigens specific to the VGCC antibody are introduced into a serum sample from the patient, allowing for the identification of antibodies as they form immune complexes by binding to these traceable antigens.